Cost-benefit analysis of arpraziquantel compared to standard of care for schistosomiasis among pre-school age children in Tanzania: an early health economic evaluation
Cost-benefit analysis of arpraziquantel compared to standard of care for schistosomiasis among pre-school age children in Tanzania: an early health economic evaluation. // The Lancet Regional Health - Africa. – URL: https://www.sciencedirect.com/science/article/pii/S3050501126001550?dgcid=rss_sd_all
Cost-benefit analysis of arpraziquantel compared to standard of care for schistosomiasis among pre-school age children in Tanzania: an early health economic evaluation. The Lancet Regional Health - Africa. https://www.sciencedirect.com/science/article/pii/S3050501126001550?dgcid=rss_sd_all
“Cost-benefit analysis of arpraziquantel compared to standard of care for schistosomiasis among pre-school age children in Tanzania: an early health economic evaluation.” The Lancet Regional Health - Africa.
@article{article69278,
title = {Cost-benefit analysis of arpraziquantel compared to standard of care for schistosomiasis among pre-school age children in Tanzania: an early health economic evaluation},
journal = {The Lancet Regional Health - Africa},
url = {https://www.sciencedirect.com/science/article/pii/S3050501126001550?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...